title: Biolimus-Eluting StenT For de-novo coRonary artery dIsease in patiENts with Diabetes mellituS: the BESTFRIENDS multicentre registry.
abstract: OBJECTIVE
  Coronary inflammation and healing influence outcomes of diabetic patients treated with Percutaneous coronary revascularization (PCI). Stents covered with biodegradable polymers (bp) may offer advantages over nonerodible polymer ones, because polymer reabsorption extinguish coronary inflammation and favours healing. Aim of our study was to assess the safety and efficacy of bp-biolimus-eluting stent (bp-BES) in a large series of consecutive diabetic patients.
  
  
  METHODS
  From 2009 to 2013 we retrospectively enrolled consecutive diabetic patients treated with PCI and bp-BES implantation. Primary end points were target lesion revascularization (TLR) and stent thrombosis rates.
  
  
  RESULTS
  Study cohort counted 747 patients. Multivessel disease was present in 48.2% with a mean stent/patient ratio of 1.860.78. During the hospital stay no stent thrombosis occurred. At 3-year follow-up we observed a 1.5% cumulative incidence of cardiac death, 1.1% of myocardial infarction and 6.3% of TLR. Stent thrombosis occurred in 1.1% of patients, all in the first 2 years of follow-up. Kaplan-Meier analysis showed a TLR-free survival at 1 and 3 years of 97.2 and 96.1%, respectively.
  
  
  CONCLUSIONS
  PCI with bp-BES seems to be well tolerated and effective in a large unselected population of diabetic patients. The good results observed were maintained at 3 years of follow-up.
authors.affiliation: aMauriziano: Meliga, Aranzulla, Scrocca, De Benedictis, Conte bMaggiore: Lupi cSan Raffaele: Latib, Sticchi, Colombo dDegli Infermi: Gagnor, Varbella eSG Bosco: Boccuzzi fCentro Medico: Alcantara gCardinal Massaia: Lombardi.
authors.forename: Emanuele
authors.initials: E
authors.lastname: Meliga
authors.forename: Alessandro
authors.initials: A
authors.lastname: Lupi
authors.forename: Azeem
authors.initials: A
authors.lastname: Latib
authors.forename: Andrea
authors.initials: A
authors.lastname: Gagnor
authors.forename: Giacomo
authors.initials: G
authors.lastname: Boccuzzi
authors.forename: Marco
authors.initials: M
authors.lastname: Alcantara
authors.forename: Primiano
authors.initials: P
authors.lastname: Lombardi
authors.forename: Alessandro
authors.initials: A
authors.lastname: Sticchi
authors.forename: Tiziana C
authors.initials: TC
authors.lastname: Aranzulla
authors.forename: Innocenzo
authors.initials: I
authors.lastname: Scrocca
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Varbella
authors.forename: Mauro
authors.initials: M
authors.lastname: De Benedictis
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
authors.forename: Maria Rosa
authors.initials: MR
authors.lastname: Conte
mesh_terms: D000368:Aged; D002317:Cardiovascular Agents / Q000008:administration & dosage; D003324:Coronary Artery Disease / Q000453:epidemiology* / Q000601:surgery; D003328:Coronary Thrombosis / Q000453:epidemiology* / Q000209:etiology; D048909:Diabetes Complications; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008800:Mexico; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000601:surgery; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*; D016016:Proportional Hazards Models; D011474:Prosthesis Design; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D062606:Tertiary Care Centers; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents